A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520315-40-00

Acronym

J3L-MC-EZEH

Enrollment

Registered

2025-06-16

Start date

2025-07-22

Completion date

Unknown

Last updated

2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate, Normal Hepatic Function and Mild, or Severe Hepatic Impairment

None listed

Sex/Gender

All

Age

18 Years to No maximum

Hungary

None listed

Source: EU CTIS · Data processed: Feb 4, 2026